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 ABSTRACT 
 
Inhibition of the mechanistic target of rapamycin (mTOR) is a promising treatment 
strategy for several cancer types. Rapamycin derivatives such as everolimus are 
allosteric mTOR inhibitors acting through interaction with the intracellular immunophilin 
FKBP12, a prolyl isomerase with different cellular functions. Although mTOR inhibitors 
have significantly improved survival of different cancer patients, resistance and lack of 
predictive factors of response remain unsolved issues. To elucidate the mechanisms of 
resistance to everolimus, we evaluated Met activation in everolimus-sensitive/resistant 
human cancer cells, in vitro and in vivo. Biochemical and computational analyses were 
performed. Everolimus-resistant cells were xenografted into mice (10/group) and 
studied for their response to everolimus and Met inhibitors. The statistical significance of 
the in vitro results was evaluated by Student’s t test. 
Everolimus reduced Met phosphorylation in everolimus-sensitive cells. This event 
was mediated by the formation of a Met-FKBP12 complex, which in turn is disrupted by 
everolimus. Aberrant Met activation in everolimus-resistant cells and overexpression of 
wild-type/mutant Met caused everolimus resistance. Pharmacological inhibition and 
RNA silencing of Met are effective in condition of everolimus resistance (P<0.01). In 
mice xenografted with everolimus-resistant cells, the combination of everolimus with 
the Met inhibitor PHA665752 reduced tumor growth and induced a statistically 
significant survival advantage (combination vs control P=0.0005). 
FKBP12 binding is required for full Met activation and everolimus can inhibit Met. 
Persistent Met activation might sustain everolimus resistance. These results identify a 
novel everolimus mechanism of action and suggest the development of clinical 
strategies based on Met inhibitors in everolimus-resistant cancers. 
 
 
 
 
 
 INTRODUCTION 
 
 
 Everolimus (RAD001) is an allosteric inhibitor of mechanistic target of rapamycin complex 1 
(mTORC1) that is effective in the treatment of different cancer types: advanced breast cancer, 
renal cell carcinoma, and neuroendocrine tumors of pancreatic origin [1-4]. It exerts its effect by 
binding to the intracellular immunophilin FK506/rapamycin binding protein 12 (FKBP12). The 
resulting inhibitory complex binds with high affinity to 2  
mTORC1 affecting downstream effectors and ultimately inhibiting tumor cell proliferation [5]. 
FKBP12 is the prototype FKBP; it contains only one FK506/rapamycin-binding domain, which 
consists of 108 amino acids. FKBP12 constitutively associates with IP3 (inositol triphosphate) [6], 
binds Ras in a palmitoylation-dependent fashion promoting retrograde trafficking of Ras, and 
also binds and regulates the activity of cellular membrane receptors endowed with kinase activity 
such as TGFbeta and EGFR [7-9].  
Everolimus have gained FDA approval for the treatment of metastatic renal cell carcinoma, for 
hormone receptor-positive, epidermal growth factor receptor 2 (HER2)-negative breast cancer 
and for pancreatic neuroendocrine tumors [10,4,11]. Clinical trials are currently ongoing on 
several tumor types, including non small cell lung cancer, gastic, ovarian, thyroid, pancreatic 
carcinomas [12]. Data from early-phase studies indicate that only a subset of patients derive 
significant clinical benefit from treatment with mTOR inhibitors [13]. The molecular basis of 
sensitivity and resistance to everolimus is largely unknown. Among the molecular mechanisms of 
resistance to mTOR inhibitors, different studies have described mutations in FKBP-12 or mTOR, 
PI3K/AKT or ERK/MAPK pathway activation via upregulation of receptor tyrosine kinases 
(RTKs), altered expression levels of eIF4E and 4E-BP1, modulation of apoptotic regulators, 
oxidative stress, enhanced angiogenesis, stimulation of autophagy [14].  
Met is a transmembrane RTK for the hepatocyte growth factor (HGF), whose ligand-induced 
activation promotes such biological activities as cell proliferation, cell invasion and protection 
from apoptosis. The HGF/Met axis drives resistance to targeted therapies in several ways, and 
preclinical data suggest that combinatorial therapies with Met inhibitors is a promising anticancer 
approach [15].  
In this study, we asked whether Met activation could affect everolimus sensitivity, and if so, 
whether pharmacological inhibition of Met could be a strategy in patients with everolimus 
resistance. 
 MATERIALS AND METHODS 
 
Compounds 
Everolimus   (RAD001),   PHA665752,   PKI-587 
and  OSI-027  were  purchased  from  Selleck  Chemicals (Germany).  Human  recombinant  
HGF  was  purchased from R&D Systems (Italy). 
 
Cell cultures 
Human renal cell carcinoma (786-O, ACHN), breast (MDA-MB-231, MDA-MB-361, T47D), 
and colorectal (HCT116) cancer cell lines were obtained between 2010 and 2013 from the 
American Type Culture Collection (ATCC). All cells were maintained according to the 
manufacturer’s protocol. Human non small cell lung cancer cell lines (PC-9 and NCI-H1975) 
were provided by Dr F. Morgillo (Second University of Naples) in 2012. 786-O EveR 
(everolimus- resistant) cells were generated according to a validated protocol of in vivo/in 
vitro selection after chronic exposure to the drug, as described [45]. 
 
Cell lines authentications 
Short tandem repeat (STR) profiles of cell lines were obtained using nine highly 
polymorphic  STR loci plus amelogenin (Cell IDTM System,  Promega). The amplified 
fragments were analyzed with the ABI PRISM 3100 Genetic Analyzer. Data analysis was 
performed by GeneMapper® software, version 4.0. Cell lines authentications was 
performed by IRCCS Azienda Ospedaliera Universitaria San Martino – Istituto Nazionale per 
la Ricerca sul Cancro (Genova, Italy). The cells were last tested between april and august 
2015. 
 
Cell density assay 
Cells  (104     cells/well)  were  grown  in  24-well plates and exposed to increasing 
doses of everolimus and   PHA665752,   alone   or   in   combination.   The percentage  of  
cell  density  was  determined  using  the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay according to the manufacturer’s instructions  (Sigma-Aldrich,  Milan,  
Italy).  The  dose- response curves for each agent alone and in combination were  
 determined  at  a  fixed  ratio  based  on  the  drug concentration causing 50% inhibition of 
cell proliferation. 
 
Transfection of small interfering RNA (siRNA) 
Transfection of siRNAs (200 pmol) targeting mTOR, Rictor, Raptor, FKBP12 and Met 
was carried out according to the manufacturer’s instructions (Dharmacon Inc., Lafayette, CO, 
USA). We used a scrambled siRNA as negative control. To evaluate target silencing, total 
protein was extracted 24 and 48 hours after transfection, and examined by western blot. 
 
Western blot and immunoprecipitation analyses 
Total protein extracts obtained from cell cultures or tumor specimens were resolved by 
4-15% SDS-PAGE and probed with anti-human, polyclonal pMet Y1349, polyclonal Met, 
monoclonal pp70S6K T412 and p70S6K (Merck-Millipore Darmstadt, Germany), monoclonal 
actin (Sigma-Aldrich, Milan, Italy), monoclonal FKBP12, polyclonal mTOR, Raptor, and 
Rictor. Co- immunoprecipitation analyses were performed with anti-Met; membranes were 
blotted with anti-FKBP12. The total lysate from 786-O, 786-O EveR and HCT116 cells 
served as positive control. Immunoreactive proteins were visualized by enhanced 
chemiluminescence (Pierce, Rockford, IL, USA). Densitometry was performed with Image J 
software (NIH, Bethesda, MD, USA). 
 
Fluorescence microscopy-confocal immunofluorescence 
786-O cells (4 x 104, seeded on sterile coverslips placed in 24-multiwell plates) were 
fixed with 4% paraformaldehyde solution and permeabilized with 0.2% triton x-100. They were 
then incubated for 1 hour at RT with monoclonal antibodies against FKBP12 (Santa Cruz-SC 
mouse, Santa Cruz, CA, USA) and polyclonal antibodies against  Met (Cell  Signaling, Beverly, 
MA, USA). Lastly, they were fluorescently labeled with the following secondary antibodies: 
Cy2-AffiniPure Donkey Anti-Rabbit IgG and Cy3-AffiniPure Donkey Anti-Mouse IgG (LiStarFish, 
Milan, Italy). Slides were mounted with glycerol 50% in PBS and imaged using a Zeiss LSM 510 
meta confocal microscope equipped with an oil immersion plan apochromat 63x objective 1.4 NA. 
 
 
 
 Subcutaneous and orthotopic murine colorectal cancer models 
We subcutaneously xenografted everolimus- resistant HCT116 cells into 50 four- to six-
week-old female BALB/c athymic nu+/nu+ (nude) mice (Charles River Laboratories, Milan, 
Italy). Forty animals were used to carry out the subcutaneous colorectal cancer model 
experiment; when tumors reached a mean volume of 1 cm3, 10 animals were euthanized, 
tumors were divided into 2-mm-sized pieces and microsurgically implanted in the cecum of 40 
Balb/C nude mice for the orthotopic experiment. See Supplementary Methods for further 
details about the surgical procedure and the treatment schedule. 
 
Statistical analysis 
The Student’s t test was used to evaluate the statistical significance of  the in vitro  
results. The statistical significance of differences in tumor growth was determined by one-way 
ANOVA and Dunnett’s multiple comparison post-test, and that of differences in survival by a 
log-rank test [46]. The linear regression test was used to evaluate the statistical significance of the 
in vitro results of everolimus-resistant cells versus sensitive cells (Graph- Pad version 5). All 
reported P values were two-sided. Analyses were performed with the BMDP New System 
statistical package version 1.0 for Microsoft Windows (BMDP Statistical Software, Los 
Angeles, CA). 
  
SUPPLEMENTARY METHODS 
 
Generation of resistant cell lines 
786-Ocells were injected subcutaneously in nude mice. When tumors reached about 0.5 cm3, 
mice were treated with everolimus 2.5 mg/kg per os, fi times a week for 8 weeks. Tumors that 
progressed under everolimus treatment were excised, and resistant cells, 786-O EveR, were 
maintained in vitro and tested for everolimus sensitivity. 
 
In vitro Met kinase inhibition assay 
 
 The Met kinase inhibition by everolimus was analyzed with a Met kinase mutant profile 
screening service by ProQinase (ProQinase GmbH, Freiburg, Germany). Briefly, compounds 
(everolimus vs PHA665752) were tested at 10 different concentrations (standard range: 3x10-
 10M–1x10- 5M; semilog dilutions) against human recombinant wt Met and nine Met mutant 
protein kinases, and IC50 values were calculated. IC50 values of Met reference inhibitor 
(PHA665752) were determined side-by-side. All assays were performed at the corresponding 
apparent ATP Km of each protein kinase using the radiometric 33PanQinase Assay™.  
 
 
 Computational analysis  
More than 60 X-ray crystal structures for Met kinase are available in PDB. Among them, we 
selected, as reference X-ray, the kinase that has: (i) a resolution below 2.00 Å; (ii) the largest 
portion of the kinase domain solved; and (iii) an active conformation. The resulting selected Met 
structure is in its unbound dually-phosphorylated state (pdb code: 3Q6U) [Rickert KW, J Biol 
Chem. 2011]. Regarding FKBP12, we selected the 1FKR NMR solution structure [Michnick SW, 
Science. 1991]. Indeed, FKBP12 undergoes great conformational changes at the 80 loop level 
[Mustafi SM, Biochem J. 2014]. Among the 20 frames available in the NMR solution structure, we 
selected the one with the greatest extension [distance (Å) between Ans43 and Gly89 Cα] at the 
80 loop level (frame 13). To generate the Met/ FKBP12 complex, we searched the whole PDB 
database for X-ray crystal structures of kinases/FKBP12 complexes. Based on results obtained, 
protein-protein docking studies were carried out only on the N-ter region of the Met N-lobe 
domain, using the HADDOCK 2.2 software web portal [de Vries SJ, Proteins. 2007; Dominguez 
Z, J Am Chem Soc. 2003]. To assess the stability and, in turn, the reliability of the generated 
Met/FKBP12 complex, a 100-ns long molecular dynamics (MD) simulation was conducted. The 
selected complex was refined by using the Protein Preparation tool available in Maestro9.1. This 
tool enables one to consider the protonation state of the amino acid residues and to 
geometrically refine the complex. Missing loops and side chains were refined using Prime. 
Subsequently, both proteins were capped with ACE and NME residues at their N-ter and C-ter 
residues, respectively. The resulting complex was embedded in an explicit water box model 
(TIP3P) and parametrized using the amber ff99SBildn force filed (final size and atom count: 105 
x 68 x 59 Å and 37.456, respectively) [http://ambermd.org/]. The system obtained was 
equilibrated using NAMD2.8 [Phillips JC, J Comput Chem. 2005], and the final MD simulation 
was conducted applying a protocol similar to that previously described [Capelli AM, J Med Chem. 
2013]. The final Met/FKBP12 complex was obtained from the cluster analysis performed on all 
the MD trajectories. The complex was aligned on the Cα atoms of Met, while the backbone 
atoms Root-mean-square deviation (RMSD) of FKBP12 was measured and used to cluster the 
 trajectories. The cluster analysis was performed using ptraj and the average-linkage algorithm 
with a cut-off value of 1 Å. Finally, the representative structure of the most populated cluster was 
choosen as the final Met/FKBP12 complex. Ptraj turned out an average structure and a 
representative structure (the frame closest to the average structure in terms of RMSD) for each 
cluster.  
 
 
 Cell transduction with lentiviral vectors  
Cells were transduced using third-generation Lentiviral vectors with the polypurine tract 
sequence [Follenzi A, Nat Genet. 2000]. As transfer vector, we used the 
pRRL.sin.PPT.hCMV.pre, where the full-length MET cDNA (4284 bp) was subcloned as a NotI-
XhoI fragment. Mutations were introduced in the human MET cDNA using a PCR-based 
technique, as described elsewhere [Bardelli A, PNAS. 1998.]. The tyrosine kinase domain of 
MET cDNA containing each mutation was substituted in the above transfer vector as SpeI-SwaI 
insert for Y1253D and M1268T mutants. We used the pRRL.sin.PPT.hCMV.GFP. pre vector as 
control. Serial dilutions of freshly harvested conditioned medium were used to infect 105 T47D 
cells in a six-well plate in the presence of Polybrene (8 μg/ml).  
 
 
 Subcutaneous murine colorectal cancer model  
Five weeks old BALB/cAnNCrlBR athymic (nu+/ nu+) mice (Charles River Laboratories, Milan, 
Italy) maintained in accordance with institutional guidelines of the University of Naples Federico II 
Animal Care Committee and in accordance to the Declaration of Helsinki were injected 
subcutaneously with HCT116  
cells (107 cells/mice) resuspended in 200 μL of Matrigel (Collaborative Biomedical Products, 
Bedford, MA, USA). Fourteen days after tumor cells injection, tumor-bearing mice were randomly 
assigned (n = 10 per group) to receive the following: everolimus 5 mg/kg per os, five times a 
week for 2 weeks; PHA665752 20 mg/kg intravenous (i.v.), five times a week for 2 weeks 
[Christensen JG, Cancer Res. 2003] or the combination of these agents. Tumor diameter was 
assessed with a vernier caliper, and tumor volume (cm3) was measured with the formula p/6 x 
larger diameter x (smaller diameter)2. Mice were sacrificed when the tumor reached the size of 
about 2 cm3, the maximum size allowed by the Ethics Committee.  
 
 Orthotopic murine colorectal cancer model  
For the orthotopic implantation in the mice cecum,the recipient animals were anesthetized with 
2,2,2-tribomoethanol 97% TBE, Avertin (Sigma-Aldrich, St. Louis, MO, USA). TBE solution was 
prepared fresh daily by mixing 0.625 g of 97% crystalline TBE powder with 25 ml sterile 0.9% 
saline, and injected intraperitoneally at 0.01 ml/g body mass (250 mg/kg). The abdomen was 
prepared with betadine solution and the surgical site was isolated in a sterile fashion. A 
laparotomy of 0.5 cm was conducted; the cecum was exteriorized and isolated using pre-cut, 
sterile gauze. A warm saline solution was used to keep the cecum wet. Subsequently, the cecum 
wall was slightly damaged with a 30G needle and a tumor fragment from HCT116 subcutaneous 
tumors was sutured to the mesenteric border of the cecum wall using 6.0 nylon surgical sutures. 
The cecum was then placed into the abdominal cavity and the abdominal wound was sutured 
using a 7.0 Ethicon absorbable stitches (Ethicon Inc., Somerville, NJ). Seven days after 
implantation, mice were randomly assigned to one of four groups (10 mice for each group) to 
receive one of the following treatments: everolimus 5 mg/kg per os, five times a week for 2 
weeks; PHA665752 20 mg/kg intravenous (i.v.), five times a week for 2 weeks [Christensen JG, 
Cancer Res. 2003] or the combination of these agents. Tumor diameter was assessed with 
ultrasonography (VEVO, Visualsonics Inc., Toronto, Canada) before treatment and once a week 
during follow-up. Body weights were monitored daily. Mice were sacrificed when, four weeks 
after tumor implantation, tumor volume of untreated mice, calculated with ultrasonography, 
reached the size of about 2 cm3, which is the maximum size allowed by the Ethics Committee. 
Primary tumors in the cecum were excised and weighed. The final tumor was measured with a 
caliper and the volume was calculated with the following formula: π/6 x larger diameter x (smaller 
diameter)2. 
 
RESULTS 
 
Everolimus inhibits Met phosphorylation in various human cancer cell lines 
We selected human cancer cell lines sensitive to everolimus: renal (786-O and ACHN), 
breast (MDA- MB-231 and MDA-MB-361), and lung (PC-9 and NCI-H1975) cancer cells. We 
first verified the in vitro sensitivity of these cell lines to everolimus in cell survival assays, and 
found that all cell lines were highly sensitive to everolimus. The concentration of everolimus 
causing 50% reduction of cell density was ≤ 0.5 µM (P < 0.0001) (Figure 1A, Supplementary 
Table S1). 
 50 
50 
and lung cell lines, decreased p70S6K phosphorylation paralleled inhibition of Met 
phosphorylation (Figure 1B). 
 
 
Met phosphorylation is not reduced after mTOR inhibition 
To evaluate if the phospho-Met reduction occurring upon everolimus treatment could 
depend from direct inhibition of the Met TK, we performed an in vitro kinase assay 
comparing the effect of everolimus with that of the Met inhibitor PHA665752 on a 
number of Met TK variants, both wild-type (wt) and mutants. As shown in Table 1, 
everolimus did not inhibit any of the isolated Met TK variants (IC > 10 µM). Conversely, 
PHA665752 inhibited Met TK variants albeit to different degrees, the effect being greatest 
against Met wt (IC 
< 100 nM). This suggested that the phospho-Met reduction could depend on mTOR 
inhibition. To test this hypothesis, we evaluated the activation/phosphorylation of Met in 
786-O and MDA-MB-231 cell lines treated with mTOR inhibitors that have different 
mechanisms of action: everolimus, an allosteric mTORC1 inhibitor that acts through 
FKBP12 binding; PKI-587, a dual PI3K-mTOR kinase inhibitor; and OSI-027, a potent and 
selective inhibitor of mTOR complexes (mTORC) 1 and 2 [17]. Phospho-p70S6K served as 
marker of activity for all mTOR inhibitors. Compared with everolimus, neither PKI-587 nor 
OSI-027 inhibited Met phosphorylation at doses that reduced phospho-p70S6K 
(Supplementary Figure S1A). 
To verify that Met phosphorylation is not directly related to mTOR inhibition, we used 
small interference RNA (siRNA) to silence different components of the mTOR complexes, 
namely, mTOR, Raptor and Rictor, in 786-O cells. mTOR partecipates in  both  mTORC1 
and mTORC2 complexes, while Raptor and Rictor are part of only mTORC1 and 
mTORC2, respectively [5]. As expected, p70S6K phosphorylation  was  inhibited by both 
mTOR and Raptor but not by Rictor siRNAs. Neither silencing of mTOR, Raptor or Rictor 
affected Met phosphorylation (Supplementary Figure S1B). These data exclude that 
everolimus-dependent inhibition of Met is related to mTOR blockade. 
 
Everolimus inhibits Met phosphorylation via FKBP12 
As everolimus exerts its  mechanism  of  action by binding to FKBP12, we asked 
 whether everolimus reduces phospho-Met via FKBP12. We first studied the intracellular 
relationship between FKBP12 and Met in 786-O cells by immunofluorescence analysis. As 
expected, Met was prevalently localized on the cell membrane, whereas FKBP12 was 
widely distributed in various intracellular compartments and in juxtamembrane regions. 
Notably, as shown in the merge staining, Met and FKBP12 partially co-localized (Figure 2A). 
To investigate in greater detail the potential functional/structural relationship between 
FKBP12 and Met, we immunoprecipitated total cell lysates from everolimus-treated and -
untreated 786-O cells with the anti- Met antibody and blotted with the anti-FKBP12 antibody. As 
shown in Figure 2B, Met co-immunoprecipitated with FKBP12, which is consistent with the partial 
co-localization observed  in  immunofl analysis. Moreover, the amount of FKBP12 co-
immunoprecipitated with Met was lower in everolimus-treated 786-O cells (Figure 2B). We also 
carried out a computational study to evaluate the experimentally  demonstrated  Met-FKBP12  
interaction at molecular level. To date, no structural information is available about the 
Met/FKBP12 complex. FKBP12 has been solved in complex with two kinases, type I TGF-β 
(TGFβI) [18] and type I activin receptor (Alk2) [19]: in both cases FKBP12 interacts with the N-ter 
region of the N-lobe of the kinase domain. Analysis of the whole eukaryotic phylogenetic tree for 
the kinase protein domain revealed that TGFβI, Alk2 and Met are in close branches (Supplementary 
Figure S2A). Docking analysis suggested that Met interacts with FKBP12 through its N-lobe 
domain (Supplementary Figure S2B). In addition, molecular dynamics simulation of the 
FKBP12/Met complex demonstrated stable specifi interactions  between  the  two  proteins  
(Supplementary Figure  S2C).  Interestingly,  a  comparison  between  the everolimus/FKBP12 
complex and FKBP12/Met suggests that Met and everolimus compete for the same FKBP12 
region (Figure 2C) 
 
 
 
Everolimus does not inhibit Met phosphorylation in everolimus-resistant cancer cell lines 
To explore how Met activation affects sensitivity to everolimus, we generated renal cell 
carcinoma 786- O EveR (everolimus-resistant) cells with acquired resistance to everolimus 
from the 786-O parental cell line (Supplementary Methods). Moreover,  HCT116 colon cancer 
cells have been used as a model of intrinsic resistance [13]. 786-O EveR and HCT116 cells 
are resistant to everolimus (Figure 3A); the concentration of everolimus causing 50% reduction 
of cell density was ≥ 5 μM (data not shown). Linear regression analysis showed that differences 
 between the slopes were statistically significant (786-O EveR vs 786-O, P <0.01; HCT116 vs 
786-O, P <0.05). Neither Met inhibition nor p70S6K phosphorylation occurred in the two cell 
lines after everolimus treatment (Figure 3B). Importantly, FKBP12 binds Met, even in a condition 
of everolimus resistance, as shown by immunoprecipitation assay (Figure 3C). Unlike data 
obtained in everolimus-sensitive models, the amount of FKBP12  co-immunoprecipitated with  
Met  was  not reduced in everolimus-treated resistant cells (Figure 3C). 
 
Met inhibition restores sensitivity to everolimus in resistant cell lines 
To investigate the role of Met in the context of everolimus resistance, we analyzed Met 
phosphorylation levels in the absence and presence of HGF in 786-O, 786-O EveR and HCT116 
cells. In everolimus-resistant cell lines high levels of phosphorylated/activated Met were detectable 
in the absence of HGF; conversely, in everolimus-sensitive cell lines phospho-Met is not 
detectable without HGF stimulation (Figure 4A). No difference in HGF expression levels were 
observed between sensitive and resistant cells (data not shown). To better defi    the contribution 
of Met to everolimus resistance, we evaluated the effect of Met inhibitor PHA665752 and Met 
silencing on everolimus- resistant cells. As shown in Figure 4B and 4C, combination of everolimus 
with both PHA665752 or Met siRNA signifi inhibits cell growth of everolimus-resistant cells, P 
<0.01 (Supplementary Table S2). As expected, in western blot analysis everolimus did not affect 
the phosphorylation of Met or p70S6K. Either PHA665752 or Met siRNA, alone and in 
combination with everolimus, reduced the phosphorylation of Met  and  p70S6K (Figure 4D, 4E). 
To evaluate whether Met activation leads to everolimus resistance, we transiently 
transfected T47D cells (physiologically not expressing Met receptor) with vectors harboring wt 
Met or constitutively active Met mutants (Y1235D and M1268T). Transfection efficiency was 
confirmed by Western blot analysis (Supplementary Figure S3A). Compared with T47D-empty 
vector, cells with wt Met, and Y1235D and M1268T mutants were resistant to everolimus; the 
drug concentration causing 50% reduction of cell density was > 0.5 μM. In these cells, 
PHA665752 significantly restored sensitivity to everolimus, P <0.01 (Supplementary Figure S3B 
and Supplementary Table S3). 
 
Met inhibition cooperates with everolimus in nude mice subcutaneously xenografted 
with resistant cells 
To investigate the simultaneous blockade of Met and mTOR in in vivo models of 
 everolimus resistance, we first performed subcutaneous transplantation of resistant HCT116 
cells in nude mice. The subcutaneous injection was used to evaluate tumor growth and mice 
survival. 
Balb/c nude  mice  subcutaneously  xenografted with everolimus-resistant HCT116 cells 
were randomly assigned to one of four groups (10 mice for each group) to receive one of 
the following treatments: everolimus 5 mg/kg per os, five times a week for 2 weeks; 
PHA665752 20 mg/kg intravenous (i.v.), five times a week for 2 weeks or the combination of 
these agents. Untreated mice reached the maximum tumor size allowed on day 42, 6 
weeks after cell injection. At this time point, everolimus and PHA665752 alone inhibited 
tumor growth by 35% and 85%, respectively, while the combination inhibited tumor growth 
by 90% (Figure 5A). PHA665752, alone and even more in combination with everolimus, 
exerted a strong and persistent antitumor activity until the end of the experiment (30% and 
65% of tumor growth inhibition, respectively). Comparison of tumor sizes, evaluated by the 
one-way ANOVA test,  was  statistically  significant for combination vs control, combination 
vs everolimus (both, P < 0.001),  and  combination  vs  PHA665752 (P < 0.05) at median 
survival of control group (Figure 5A). Consistently, 50% of mice treated with the everolimus/ 
PHA665752 combination were alive at the end of the experiment. Median survival in the 
combination-treated mice was significantly longer than in control mice and in everolimus-
treated mice, but not in mice exposed to PHA665752 (Figure 5B and Supplementary 
Table S4). Both everolimus and PHA665752 were well tolerated, and no significant loss 
of animal weight was observed in mice exposed to combined treatment. These data are 
consistent with the efficacy of PHA665752 in combination with rapamycin, previously 
demonstrated by Ma et al [20]. 
 
Met inhibition cooperates with everolimus in nude mice orthotopically xenografted with 
resistant cells 
To further investigate the simultaneous blockade of  Met  and  mTOR  in  in  vivo  
models  of  everolimus resistance, we also performed orthotopic transplantation of resistant 
HCT116 cells in nude mice. The orthotopic model was used to evaluate growth and invasion 
of tumor cells in their natural location. When orthotopic tumors, assessed with micro-
ultrasonography, reached a mean volume of 0.6-0.7 cm3, mice were randomly divided into 
four groups (10 mice/group) to receive everolimus 5 mg/ kg per os, five times a week for 2 
weeks, PHA665752 20 mg/kg intravenous (i.v.), five times a week for 2 weeks or their 
 combination. Untreated mice reached the maximum tumor size allowed, about 2 cm3, four 
weeks after tumor implantation. At this time point, mice were sacrificed, primary tumors 
excised and tumor volume/ weight measured (Supplementary Methods). Only 5 
mice/group survived, the other animals died from bowel obstruction during the experiment. 
As depicted in Figure 5C and Supplementary Figure S4, there were large tumors in the 
cecum and peritoneum of mice treated with vehicle and with everolimus. Treatment with 
PHA665752 greatly reduced tumor volume (Figure 5C) and tumor weight (Figure 5D); this 
effect was more pronounced with combination treatment. Comparison of tumor volume and 
tumor weight was statistically significant for combination vs control (P = 0.0001 and P = 
0.008, respectively) and for combination vs everolimus (P = 0.0016 and P = 0.016, 
respectively), but not for  combination  vs  PHA665752 (P = 0.326 and P = 0.371, 
respectively). Western blot analysis of tumors removed at the end of the experiment showed 
that the combination reduced the phosphorylation of both p70S6K and Met (Figure 5D). 
 
 
 
 
DISCUSSION 
 
One of the great challenges of cancer research is to tailor therapy to each cancer 
patient. Consequently, the mechanisms of action of targeted therapies and the causes of 
limited therapeutic responses must be carefully assessed [21]. To date, everolimus, an orally 
available mTOR inhibitor approved for the treatment of advanced breast cancer, 
neuroendocrine tumors of pancreatic origin, and advanced renal cell carcinoma, has met 
multiple clinical needs in oncology [1]. The existence of negative feedbacks on RTKs sustained 
by p70S6K has been described for IGFR1 [22-27; 16] and platelet-derived growth factor 
receptor (PDGFR) [28]. Herein, we demonstrate that everolimus inhibits activation of the Met 
RTK in various everolimus-sensitive cancer cell lines. These results are consistent with previous 
data demonstrating Met dephosphorylation after everolimus treatment [29]. In our hands this 
effect is strictly related to interaction between FKBP12 and Met and not to the mTOR/ p70S6K 
axis. The  FKBP family includes  immunophilin proteins endowed with prolyl isomerase activity 
[30] that interact with kinases and hormone receptors and thus probably play  a  relevant  role  
in  pathological  processes as cancer [31]. FKBPs are implicated in cell growth and survival, 
 in apoptotic signaling pathways, and moreover their expression was shown to differ between 
cancer tissues and non-tumor samples [32]. Various functions have been attributed to FKBPs: 
FKBP52 regulates steroid hormone receptors in breast and prostate cancer cells [33-35], 
FKBP51 regulates Akt [36] and NF-kB pathways [37], and FKBP65 is able to directly interact 
with cRAF-1 [38]. Interestingly, changes in intracellular FKBP12 levels could modulate EGFR  
autophosphorylation  levels,  which  suggests  that FKBP12 functions as an endogenous 
inhibitor of EGFR activation [8,39]. FKBP12 also acts as an interactor and a regulator of the 
type I serine/threonine kinase receptor of the TGF-beta superfamily [9,18,40,41]. 
We have identified a new role of FKBP12, namely, as a regulator of Met activation, which is 
supported by a phylogenetic rationale. Indeed, FKBP12 interacts with the N-lobe of the kinase 
domains of type I TGF-β and type I activin receptors (TGFβI and Alk2, respectively) that are 
phylogenetically closed to Met [40,19]. This suggests that, like TGFβI and Alk2, also Met should 
be able to make direct contact with FKBP12 through its N-lobe kinase domain. In this 
context, everolimus, by disrupting the FKBP12/Met complex, could facilitate Met inactivation. 
Resistance to everolimus prevents the dissociation of the FKBP12/Met complex, thus avoiding 
Met inactivation. 
We suggest that increased Met activation could induce everolimus resistance. Little is 
known about factors predictive of response to everolimus, or about the mechanisms underlying 
everolimus resistance. Mutations in tuberous sclerosis complex 1 (TSC1) and 2 (TSC2), which 
encode negative regulators of the mTOR pathway, confer sensitivity to everolimus [42,43], while 
mutations in mTOR or FKBP12 induce resistance [44]. Also aberrant activation of the PI3K/Akt or 
Ras/MAPK pathways have been implicated in everolimus resistance, however, we are still far from 
fully understanding how everolimus resistance is established, how to treat everolimus refractory 
patients and how to identify everolimus sensitive patients [14]. In our hands, Met inhibition by 
both siRNA and PHA665752 produced a reduction in the activation/phosphorylation of p70S6K. In 
some cases, the combination of everolimus with Met inhibition did not potentiate this effect. 
Therefore, we hypothesize that activation of p70S6K could be one of the mechanisms through 
which activation of Met contribute to everolimus resistance. 
In conclusion, our experimental data have potentially relevant clinical implications. First, we 
assign a new role to FKBP12, as a regulator of Met activation. Second, we suggest that 
everolimus should  be  considered not  only an allosteric mTOR inhibitor, but also a Met 
inhibitor. Therefore, Met expression/activation could serve as a predictive  biomarker  of  
sensitivity  to  everolimus.  Even if our results did not show synergism of action between 
 everolimus and PHA665752, we found that Met inhibitor is effective in condition of everolimus 
resistance. Therefore, we suggest Met inhibition as an effective strategy to be used, secondarily 
to everolimus,in cancer patients affected by tumors with intrinsic or acquired resistance to 
everolimus. 
 
 
 
FIGURES AND TABLES 
 
 
 
Figure 1: Everolimus is effective and inhibits Met phosphorylation in different human 
cancer cell lines. A. Percent of cell density of human renal cell carcinoma (786-O, ACHN), 
breast (MDA-MB-231, MDA-MB-361), non small cell lung cancer (PC-9, NCI-H1975) cells 
treated for 72 hours with everolimus (0.1 - 2.5 µM), as measured by MTT assay. Data 
 50 
represent the mean (±SD) of three independent experiments, each performed in triplicate. 
Bars, SDs. B. Western blot analysis of protein expression in 786-O, ACHN, MDA- MB-231, 
MDA-MB-361, PC-9, NCI-H1975 cells treated for 24 hours with everolimus (0.5 µM). The 
relative optical density of phospho- protein levels normalized to total protein levels is shown. 
 
 
 
Table 1: Effect of everolimus on Met TK catalytic activity 
 
 D1228
H 
D1228
N 
F1200I M1250
T 
Wild-
type 
Y1230
A 
Y1230
C 
Y1230
D 
Y1230
H 
Compound IC50 
(µM) 
IC50 
(µM) 
IC50 
(µM) 
IC50 
(µM) 
IC50 
(µM) 
IC50 
(µM) 
IC50 
(µM) 
IC50 
(µM) 
IC50 
(µM) 
everolimus >10 >10 >10 >10 >10 >10 >10 >10 >10 
PHA665752 4.37 6.35 0.734 0.108 0.0185 4.22 3.57 7.92 1.88 
Compound concentrations in the assay from 0.3 nM to 10 µM, semi-long step, singlicate 
measurement. 
Ranking of IC values: 
 
IC50 (µM) above 10 
IC50 (µM) between 10 and 1 
IC50 (µM) between 1 and 0.1  
IC50 (µM) below 0.1 
 
 
 
  
 
Figure 2: Everolimus inhibits phospho-Met phosphorylation via FKBP12. A. 
Colocalization analysis performed by immunofluorescence analysis: 786-O cells were grown 
on glass cover slips for 24 hours, then double-stained with anti-Met receptor and anti-
FKBP12 primary antibodies and incubated with the appropriate rhodamine- or fluorescein-
tagged goat anti-mouse or anti-rabbit antibody. B. Immunoprecipitation (IP) assay: 786-O 
cells, cultured in complete medium or treated for 24 hours with everolimus (0.5 µM), were 
immunoprecipitated using anti-Met antibody (Met Ab) and blotted with anti-Met and anti-
FKBP12 antibodies. The same samples with normal IgG served as negative control. C. 
Computational analysis. Left: Calculated FKBP12/Met complex. FKBP12 is shown as orange 
ribbons while Met is shown as white and cyan surface for the N- and C-lobe, respectively. 
Top right: RMSD calculated for the FKBP12 backbone atoms along the 100-ns molecular 
dynamics simulation with respect to the FKBP12/Met average complex calculated over the 
100 ns MD simulation. Bottom right: Everolimus/FKBP12 complex. The protein is shown as 
orange ribbons and the ligand as white and red spheres. The complex was calculated starting 
from the published X-ray rapamycin/FKBP12 complex. 
 
 
  
 
 
 
 
Figure 3: Everolimus does not inhibit Met phosphorylation in human everolimus 
resistant cancer cell lines. A. Percent of cell density of 786-O, 786-O EveR and HCT116 
cells treated for 72 hours with everolimus (0.1–2.5 µM), as measured by MTT assay. Data 
represent the mean (±SD) of three independent experiments, each performed in triplicate. 
Bars, SDs. B. Western blot analysis of protein expression in 786-O EveR and HCT116 cells 
treated for 24 hours with everolimus (0.5 µM). The relative optical density of phospho-protein 
levels normalized to total protein levels is shown. C. Immunoprecipitation assay: 786-O 
EveR and HCT116 cells, cultured in complete medium and treated for 24 hours with 
everolimus (0.5 µM), were immunoprecipitated using anti-Met antibody and blotted with anti-
Met and an anti-FKBP12 antibodies. The same samples with normal IgG served as negative 
control. 
 
  
 
Figure 4: Met inhibition restores sensitivity to everolimus in resistant cell lines. A. 
Western blot analysis of Met and phospho- Met in 786-O, 786-O EveR and HCT116 cells. Cell 
were cultured without serum for 24 hours or treated with HGF 50 ng/ml for 60 minutes. The 
relative optical density of phospho-protein levels normalized to total protein levels is shown. B. 
Percent of cell density of 786-O EveR and HCT116 cells treated for 72 hours with everolimus 
(1 µM), PHA665752 (1 µM) and combinations of both drugs as measured by MTT assay. **, 
2-sided P < 0.01, combination versus PHA665752 alone. Data represent the mean (±SD) of 
 three independent experiments, each performed in triplicate. Bars, SDs. C. Percent of cell 
density of 786-O EveR and HCT116 cells treated for 72 hours with everolimus (1 µM), siRNA 
Met (50 nM) and combinations of both as measured by MTT assay. **, 2-sided P < 0.01, 
combination versus Met siRNA alone. Data represent the mean (±SD) of three independent 
experiments, each performed in triplicate. Bars, SDs. D. Western blot analysis of protein 
expression in 786-O EveR and HCT116 cells treated for 24 hours with everolimus (1 µM), 
PHA665752 (1 µM) and combination of both drugs. The relative optical density of phospho-
protein levels normalized to total protein levels is shown. E. Western blot analysis of protein 
expression in 786-O EveR and HCT116 cells treated for 24 hours with everolimus (1 µM), 
siRNA Met (50 nM) and combination of both. The relative optical density of phospho-protein 
levels normalized to total protein levels is shown. 
 
 
 
 
 
 
 
 
  
 
Figure 5: Inhibition of Met cooperate with everolimus in in vivo models of everolimus 
resistance. A. Graph (box plots) shows tumor volumes of HCT116 orthotopic murine 
cancer models randomized (10/group) to receive everolimus, PHA665752 or their 
combination, as described in the Methods section. The horizontal line is a median (50th 
percentile) of the measured volumes, the top and bottom of the boxes represent 25th and 
95th percentiles, respectively, and whiskers indicate the range from the largest to smallest 
observed data points within 1.5 interquartile range presented by the box. Comparison of 
tumor volume was statistically significant for both combination vs control and combination vs 
everolimus (P < 0.005), but not for combination vs PHA665752 (P = 0.326). B. Graph (box 
plots) shows tumor weights of HCT116 orthotopic murine cancer models randomized 
(10/group) to receive everolimus, PHA665752 or their combination, as described in the 
Methods section. The horizontal line is a median (50th percentile) of the measured volumes, 
the top and bottom of the boxes represent 25th and 95th percentiles, respectively, and 
whiskers indicate the range from the largest to smallest observed data points within 1.5 
interquartile range presented by the box. Comparison of tumor weight was statistically 
significant for both combination vs control and combination vs everolimus (P < 0.05), but not 
 for combination vs PHA665752 (P = 0.371). C. Western blot analysis was performed on total 
lysates from tumor specimens of mice sacrificed. Tumors derived from each treatment group 
were pooled during lysis to obtain a single specimen. D. Graph show tumor volume of 
HCT116 subcutaneous murine cancer models randomized (10/ group) to receive everolimus, 
PHA665752 or their combination, as described in the Methods section. The one-way ANOVA 
test was used to compare tumor sizes among treatment groups at the median survival time 
of the control group (37 days). The results are statistically significant for the combination vs 
control (P < 0.0001), everolimus (P < 0.0001), or PHA665752 (P < 0.05). Bars, SDs. E. 
Graph show survival of HCT116 subcutaneous murine cancer models randomized (10/group) 
to receive everolimus, PHA665752 or their combination, as described in the Methods section. 
Median survival differences were statistically significant for the combination vs control (P = 
0.0005) and combination vs everolimus (P = 0.0022), but not for combination vs PHA665752 
(P = 0.446, log-rank test)
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Supplementary Figure S1: Met phosphorylation is not reduced after mTOR inhibition.1 
A. Western blot analysis of protein expression in 786-O cells and MDA-MB-231cells treated for 24 
hours with everolimus (0.5 µM), PKI-587 (0.5 µM) or OSI-027 (0.5 
µM). The relative optical density of phospho-protein levels normalized to total protein levels is 
shown. B. Western blot analysis of protein expression in 786-O cells treated for 48 hours with 
scrambled, mTOR, Raptor, and Rictor siRNAs. The relative optical density of phospho- protein 
levels normalized to total protein levels is shown. 
  
 
 
 
Supplementary Figure S2: FKBP12 interacts with Met. A. Phylogenetic tree of the whole 
eukaryotic kinome. The phylogenetic tree was obtained from the kinase.com “Genomics, evolution 
and function of protein kinases” project, at http://kinase.com/web/current/ human/phylogeny. The 
circular tree and the phylogram were generated with TreeDyn. The kinases of interest are indicated. 
B. Region considered for the docking studies. FKBP12 is depicted as orange cartoon and sticks, 
while Met as white ribbons. Cyan cartoons depict the region of Met considered for the docking 
studies. The table shows the residue numbers (full length numeration) corresponding to the region 
considered for the docking studies. C. Top: Three-dimensional representation of the key interaction 
 established by FKBP12 and Met. FKBP12 is depicted as orange ribbons and sticks, Met as white 
surface sticks and spheres. Bottom: Schematic plot of the most stable interactions established by 
FKBP12 (orange labeled residues) and Met (black labeled residues). 
 
 
 
 
Supplementary Figure S3: Met constitutive activation correlates with everolimus 
resistance. A. Western blot analysis of Met in T47D cells transduced with lentiviral empty vector 
versus lentiviral vector harbouring Met wt, Met with Y1235D mutation and Met with M1268T 
mutation. B. Percent of cell density of T47D transiently transduced with empty vector, with Met wild 
type, with the Met Y1235D and Met M1268T mutations and treated for 72 hours with everolimus (1 
µM), with PHA665752 (1 µM) or with a combination of both as measured by MTT assay. **, 2-sided 
P < 0.01, combination versus PHA665752 alone. Data represent the mean (±SD) of three 
independent experiments, each performed in triplicate. Bars, SDs. 
  
 
 
 
Supplementary Figure S4: A combination of Everolimus and PHA665752 inhibits growth 
of orthotopic HCT116 CRC xenografts. HCT116 cells were injected into the cecal wall of nude 
mice. Two weeks later, the mice were randomly assigned (10 mice each group) to receive: 
everolimus 5 mg/kg per os, five times a week for 2 weeks; PHA665752 20 mg/kg intravenous (i.v.), 
five times a week for 2 weeks or the combination of these agents. The treatment continued for 2 
weeks, and 1 week later mice were killed and necropsied. Pictures of the animals included in the 
experiment (5 mice each group) are shown. 
 
 
 
 
 
 
  
Supplementary Table S1: P values for cell density reduction by everolimus vs control in 
different human cancer cell lines, measured by MTT assay 
 
Cell lines 0.1 μM 0.5 μM 1 μM 2.5 μM 
786-O < 0.001 < 0.001 < 0.001 < 0.001 
ACHN < 0.001 < 0.001 < 0.001 < 0.001 
MDA-MB-
231 
< 0.001 < 0.001 < 0.001 < 0.001 
MDA-MB-
361 
< 0.001 < 0.001 < 0.001 < 0.001 
PC-9 < 0.001 < 0.001 < 0.001 < 0.001 
H1975 < 0.001 < 0.001 < 0.001 < 0.001 
 
Supplementary Table S2: P values for cell density reduction by everolimus plus 
PHA665752 vs PHA 665752 alone in 786-O EveR and HCT116 cell lines. P values for survival 
inhibition by everolimus plus siRNA Met vs siRNA Met in 786-O EveR and HCT116 cell lines 
 
Cell line  p value 
786-O EveR combination vs PHA665752 < 0.001 
HCT116 combination vs PHA665752 0.009 
786-O EveR combination vs siRNA Met < 0.001 
HCT116 combination vs siRNA Met 0.002 
 
 
Supplementary Table S3: P values for cell density reduction by everolimus plus PHA 
665752 vs PHA 665752 alone in T47D cells transfected with Met wild type, Met Y1253 or Met 
M1268T mutant variants 
 
T47D  P value 
Met wild type combination vs PHA665752 0.002 
Met Y1253D combination vs PHA665752 0.007 
Met M1268T combination vs PHA665752 < 0.001 
 
 
 
 
 
  
 
Supplementary Table S4: Statistical analysis of mice survival in the HCT116 
subcutaneously xenografted model 
 
 Median survival Hazard ratio 95% CI P value 
Combination vs control 68 vs 37 0.1093 0.03147-0.3799 0.0005 
Combination vs everolimus 68 vs 37.5 0.154 0.04644-0.5104 0.0022 
Combination vs PHA665752 68 vs 57 0.6316 0.1937-2.059 0.446 
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